Table 6 Overview of anti-HLA antibodies detected before and after allogeneic bone-forming cell implantation (safety population)
Anti-HLA antibody | Baseline (N = 22) n (%) | Week 2 (N = 22) n (%) | Month 1 (N = 22) n (%) | Month 3 (N = 21) n (%) | Month 6 (N = 22) n (%) |
|---|---|---|---|---|---|
Anti-HLA-positive patients | |||||
 Anti-HLA class I antibodies (Luminex I) | 4 (18.2) | 5 (22.7) | 9 (40.9) | 12 (57.1) | 13 (59.1) |
 Anti-HLA class II antibodies (Luminex II) | 6 (27.3) | 6 (27.3) | 6 (27.3) | 7 (33.3) | 8 (36.4) |
 Anti-HLA class I/II antibodies (Luminex I/II) | 8 (36.4) | 8 (36.4) | 10 (45.5) | 12 (57.1) | 13 (59.1) |
ALLOB-specific anti-HLA-positive patients | |||||
 Anti-HLA class I antibodies (Luminex I) | 4 (18.2) | 4 (18.2) | 9 (40.9) | 12 (57.1) | 13 (59.1) |
 Anti-HLA class II antibodies (Luminex II) | 3 (13.6) | 3 (13.6) | 4 (18.2) | 4 (19.0) | 3 (13.6) |
 Anti-HLA class I/II antibodies (Luminex I/II) | 5 (22.7) | 5 (22.7) | 9 (40.9) | 12 (57.1) | 13 (59.1) |